A comparison of outcomes from a regional Mesothelioma MDT against the National Lung Cancer Audit (NLCA) Mesothelioma standards

Ahmed, Maryam; Lyons, Judith; Jackson, Susan; Sharman, Anna; Dixon, Mairead; Taylor, Paul D.; Holme, Jayne; Evison, Matthew

doi:10.1183/13993003.congress-2018.pa2889

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mesothelioma MDTs also obviate the need for post-mortem examination [15]. Ahmed et al found documentation of PS status, treatment rates and access to clinical research to be improved with their regional MDT [17]. Northumbria HealthCare also employs the only regional Mesothelioma UK nurse and access to those specific services will be increased if all patients are discussed in one MDT.…”

Section: Discussionmentioning

confidence: 99%

A review of malignant pleural mesothelioma in a large North East UK pleural centre

Murphy

Mount

Starkie

et al. 2020

Pleura and Peritoneum

View full text Add to dashboard Cite

ObjectivesThe National Mesothelioma Audit 2020 showed Northumbria to have low rates of histopathological confirmation, treatment and one-year survival rates for malignant pleural mesothelioma (MPM). We hypothesized that an internal analysis over a 10-year period provides valuable insights into presentation, diagnosis, treatment and outcomes.MethodsA single-centre retrospective case series of all confirmed MPM patients between 1 January 2009 and 31 December 2019 was performed. Demographics, clinical, radiological and histopathological characteristics and outcomes were collected. Statistical analysis was performed using SPSS V26.0.ResultsA total of 247 patients had MPM. About 86% were male, mean age 75.7 years. Dyspnoea (77.4%) and chest pain (38.5%) were commonest symptoms. 64.9 and 71.4% had pleural thickening and effusion, respectively. About 86.8% had at least one attempt to obtain a tissue biopsy, but histopathological confirmation in only 108 (43.7%). About 66.3% with PS 0 and 1 (62.7% of total cohort) had at least one anti-cancer therapy. Death within 12 months was associated with disease progression within 6 months (p≤0.001). Chemotherapy (p≤0.001) and epithelioid histological subtype (p=0.01) were protective.ConclusionsThis study confirms known epidemiology of MPM, demonstrates variability in practices and highlights how some NMA recommendations are not met. This provides the incentive for a regional mesothelioma multi-disciplinary meeting.

show abstract

Section: Discussionmentioning

confidence: 99%